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Background: Cancer is one of the most prominent human diseases which has enthused scientific and commercial
interest in the discovery of newer anticancer agents from natural sources. Here we demonstrated the anticancer
activity of ethanolic extract of aerial parts of Pupalia lappacea (L) Juss (Amaranthaceae) (EAPL) on Chronic Myeloid
Leukemia K562 cells.
Methods: Antiproliferative activity of EAPL was determined by MTT assay using carvacrol as a positive control.
Induction of apoptosis was studied by annexin V, mitochondrial membrane potential, caspase activation and cell
cycle analysis using flow cytometer and modulation in protein levels of p53, PCNA, Bax and Bcl2 ratio, cytochrome
c and cleavage of PARP were studied by Western blot analysis. The standardization of the extract was performed
through reverse phase-HPLC using Rutin as biomarker.
Results: The results showed dose dependent decrease in growth of K562 cells with an IC50 of 40 ± 0.01 μg/ml by
EAPL. Induction of apoptosis by EAPL was dose dependent with the activation of p53, inhibition of PCNA, decrease
in Bcl2/Bax ratio, decrease in the mitochondrial membrane potential resulting in release of cytochrome c, activation
of multicaspase and cleavage of PARP. Further HPLC standardization of EAPL showed presence 0.024% of Rutin.
Conclusion: Present study significantly demonstrates anticancer activity of EAPL on Chronic Myeloid Leukemia
(K562) cells which can lead to potential therapeutic agent in treating cancer. Rutin, a known anti cancer compound
is being reported and quantified for the first time from EAPL.
Keywords: Pupalia lappacea, Anticancer activity, Chronic myeloid leukemia (K562) cells, Cytochrome c, p53,
Multicaspase, PCNABackground
Plant derived natural products gaining importance to
cure various disease conditions. Side effects of several
allopathic drugs and development of resistance to cur-
rently used drugs have led to increased emphasis on the
use of plant materials as a source of medicines for a
wide variety of human ailments. Incidentally plants and
herbs are persistently being studied for the identification
of novel therapeutic agents. Among the 2, 50,000 higher
plant species on earth, more than 80,000 plants have
medicinal values. India is one of the biodiversity centers
with the presence of over 45,000 different plant species.
Of these, about ~20,000 plants have good medicinal
value. However, only ~7500 species are used for their* Correspondence: ravi_alvala@yahoo.co.in
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reproduction in any medium, provided the ormedicinal values by traditional communities. It is well
established that plants have always been useful source,
for occurrence of anticancer compounds [1-3]. Approxi-
mately 60% of currently used anticancer chemotherapeu-
tic drugs (vinblastin, vincristine) are derived from plant
resource [4,5]. Moreover, traditionally, plants passed em-
pirical testing against specific diseases and demonstrated
that they are well tolerated in humans. Even though
quite a few medicinal plants are applied against a wide
variety of conditions, there are still numerous plants that
have not been cross-tested in diseases apart from the
traditional applications; one of such plant is Pupalia
lappacea.
Pupalia lappacea (L) Juss. (Amaranthaceae) is an erect
or straggling under shrub found in the hedges of fields
and waste places from Kashmir to Kanyakumari and
commonly known as forest Burr or creeping cock’s. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lappaceae with edible oil is used to treat bone fractures
and inflammatory conditions [6]. The fruit juice is ap-
plied locally for cuts, mixed with palm oil to treat boils
and the fruit soup is used for cough and fever. In Africa,
fruit is used as an ingredient in enema preparation;
mixed with palm oil, it is applied as a dressing for boils
and also applied to leprosy sores after making them
bleed. Burnt plant is mixed with water to treat flatu-
lence. Traditionally it is also used to treat jaundice, ab-
dominal colics, cephalgias, diarrheas, paralysis, erectile
dysfunction, vomiting and malaria [7]. Chemical investi-
gations of P. lappacea revealed that foliage of this plant
consists of 8 compounds, namely 1-docosanol, stearic
acid, stigmasterol, sitosterol, N-benzoyl-L-Phenyl alaninol
acetate, setosterol-3-O-D-glucopyranoside, stigmasterol-
3-O-D-glucopyranoside and 20- hydroxyl ecdysone[8]
The seeds are reported to consist of glycosides, saponins,
steroids and alkaloids [9]. Aladedunye et al., reported
the antioxidant activity of hexane and dichloromethane
extract of P. lappacea foliage [8]. Sowemimo et al., in
his preliminary studies reported the cytotoxic activity of
whole plant of P. lappacea on HeLa cells [10]. Many of
the natural antioxidants like curcumin, quercetin, resver-
atrol, berberine etc., are reported for potent anticancer
activity in-vitro and in-vivo. Because of ethical considera-
tions and the substantial time and expense required
when using animal models, human cancer cell lines are
preferred for most preliminary anticancer screening
studies. The ability to inhibit cancer cell proliferation is
considered as an indicator of anticancer potential, be-
cause the balance of tumor cell proliferation over cell
death has been proposed to be one of the key factors in
cancer evolution and progression. The present study was
aimed to investigate in vitro anti proliferative activity of
EAPL on K562 cells which is a proposed model for
study of most of the cytotoxicity studies [11].
Methods
Plant material
The whole plant of P. lappacea was collected during flower-
ing season from the Osmania University campus, Hydera-
bad, Andhra Pradesh, India, in the month of October 2010.
Identification of plant was done by Dr. G. Bhagyanarayana,
Taxonomist, Department of Botany, Osmania University,
Hyderabad, India. The aerial parts (without flowers) were
separated, cleaned, air dried and grounded to powder. The
voucher specimen (PUL-203-07) is being maintained in
department of Pharmacognosy, G. Pulla Reddy College of
Pharmacy, Hyderabad, India.
Preparation of plant extract
The dried powder of aerial parts (1000 g) was extracted
with 80% aqueous ethyl alcohol (5 liters) at roomtemperature by maceration for 7 days. The extract was
filtered and concentrated under reduced pressure in ro-
tary flash evaporator. The concentrated organic extract
was lyophilized to remove the moisture and traces of
solvent. The final yield of aerial part was 1.85% (18.5 g).
The lyophilized product was qualitatively tested for the
presence of phytoconstituents by TLC and test tube
reactions [12,13].
Chemicals
3- (4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT), carvacrol were purchased from Sigma–
Aldrich (Bangalore, India), Phosphate-buffered saline
(PBS), RPMI medium, fetal bovine serum (FBS) were
purchased from Gibco BRL (CA, USA). ECL reagent kit
was purchased from GE Amersham whereas Nitrocellu-
lose membrane from Millipore (Bangalore, India).
Mouse monoclonal antibody against cytochrome c was
from ChemiCon (CA, USA). Monoclonal antibodies of
PARP (Poly (ADP-ribose) polymerase), BCl2 ((B-cell
lymphoma 2) and Bax were procured from Upstate
(Charlottesville, VA, and USA). All the other chemicals
and reagents used were of analytical and molecular
biology grade.
Determination of effect of EAPL on cell proliferation by
MTT assay
Cell culture
Human chronic myeloid leukemia K562 cells, Human
embryonic kidney HEK-293 cells were procured from
National Center for Cell Sciences, Pune, India. Cells
were grown in RPMI media supplemented with 10% heat
inactivated fetal bovine serum (FBS), 100 IU/ml penicil-
lin, 100 mg/ml streptomycin and 2 mM-Glutamine. Cul-
tures were maintained in a humidified atmosphere with
5% CO2 at 37°C. The cells were subcultured twice a week,
seeding at a density of about 2*103 cells/ml. cell viability
was determined by the trypan blue dye exclusion method.
Cell proliferation assay
Cell viability was determined by MTT assay. 5 × 103
cells/well (K562 and HEK-293) were seeded to 96-well
culture plate and cultured with or without extract (10,
20, 30, 40, 50, 60, 70, 80, 90 & 100 μg/ml) or carvacrol
(0, 0.5, 1, 10, 50,100 and 150 μg/ml) for 24 h in a final
volume of 200 μl. After treatment, the medium was
removed and 20 μl of MTT (5 mg/ml in PBS) was added
to the fresh medium. After 3 h incubation at 37°C, cells
were suspended in 100 μl of DMSO and plates were agi-
tated for 1 min. Absorbance at 570 nm was recorded in
a multi-well plate reader (Victor3 TM, Perkin Elmer,
USA). Percent inhibition of proliferation was calculated
as a fraction of control (without extract).
(a) (b)
Figure 1 MTT assay: Cells treated with EAPL (a), Carvacrol for 24 h in K562 cell lines (b). Values were expressed as mean ± SEM (P < 0.05).
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Cell culture
1*104 cells/well were seeded in 96 well plates and incu-
bated for 2–3 hrs at 37°C in humidified 5% CO2 envir-
onment. Cells were treated with different concentrations
(0, 25, 50, 100 μg/ml) of EAPL for 24 hrs, then har-
vested, stained and analyzed by Guava EasyCyte system
for following experiments.
Annexin V assay
The Guava Nexin assay was conducted according to the
manufacturer’s protocol. Briefly, cells after harvesting,
resuspended in 50 μl complete RPMI medium. A volume
of 150 μl staining solution (135 μl 1X apoptosis buffer,
10 μl Annexin V-PE, and 5 μl of 7-AAD) was then added
to each well, incubated in the dark at room temperature
for 20 min and acquired by using Guava EasyCyte sys-
tem (5*103 cells counted/sample, flow rate setting
medium). The Nexin intensity gates were set to position
the live population in the lower left corner of the dot
plot. The angles of the gates were then positioned to div-
ide the dot plot into four quadrants. Each quadrant of
the dot plot contains a distinct population of cells that is
dependent on the presence and intensity of cellular
stains per cell.(a) (b
Figure 2 Microscopic photographs: untreated (a), treated (100 μg/ml)Cell cycle analysis
Cell cycle analysis was conducted following the manu-
facturer’s instructions. After harvesting, cells were
washed with 1X PBS twice, and then fixed overnight at
−20°C in 70% ethanol. After fixing, stained for DNA
content with propidium iodide, and acquired by using
Guava EasyCyte system (5*103cells counted/sample, flow
rate setting medium). The cell cycle gates were set to a
position in dot plot which corresponds to four markers
showing marker 1: G1 phase, marker 2: S phase, marker
3: G2/M phase and marker 4: sub-G0/G1 cells in
histogram.
Mitochondrial membrane potential analysis
The Guava MitoPotential assay was conducted according
to manufacturer’s instructions. Briefly after harvesting,
cells were resuspended in 200 μl of medium. A volume
of 2 μl 100X JC-1 solution and 2 μl of 7-AAD was then
added to each well. Plates were incubated for 30 minutes
at 37°C in a 5% CO2 incubator and acquired on a Guava
EasyCyte system (5*103cells counted/sample, flow rate
setting medium). The membrane mitopotential intensity
gates were set to position the live population in the
lower left corner of the dot plot. The angles of the gates
were then positioned to divide the dot plot into four)
(b) cells. Arrows indicate apoptotic cells.
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tinct population of cells that is dependent on the pre-
sences and intensity of cellular stains per cell. Finally
percentage of apoptotic/dead cells corresponding to live
cells was shown in dot plot.
Multicaspase activity analysis
Activation of multicaspase by EAPL was performed on
Guava Easy Cyte Flow cytometer. Cells treated with EAPL
were harvested, washed with PBS, stained with SR-VAD-
FMK, 7-AAD and analyzed by flow cytometry according
to manufacturer’s protocol (5*103cells counted/sample,
flow rate setting medium). The activation of multicaspase
intensity gates were set to position the live population inFigure 3 Annexin V assay: 5 x 103 cells were treated with EAPL at dif
(a) Control (b) 25 μg/ml (c) 50 μg/ml (d) 100 μg/ml. UL-Dead cells. UR-Late
represents the % apoptotic cells (mean ± SEM).the lower left corner of the dot plot. The angles of the
gates were then positioned to divide the dot plot into four
quadrants. Each quadrant of the dot plot contains a dis-
tinct population of cells that is dependent on the presence
and intensity of cellular stains per cell.
Western blot analysis
Western blot analysis was performed as previously
described [14]. Briefly, cells were lysed in a lysis buffer and
centrifuged (10,000 × g) for 10 min. The protein content
of the supernatant was determined according to the
Bradford method [15] and used as the whole-cell extracts.
Proteins (100 μg) were separated on 8–12% sodium dode-
cyl sulphate - polyacrylamide gels (SDS-PAGE) along withferent concentrations for 24 h analyzed by flow cytometer.
apoptotic cells. LR-Early apoptotic cells LL-live cells. Bar graph
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ally transferred to nitrocellulose membrane (Bio-Rad La-
boratories, Hercules, CA). Non specific binding sites on
the membranes were blocked with 5% (w/v) nonfat dry
milk after checking the transfer using 0.5% Ponceau S
in 1% acetic acid and then probed with a relevant antibody
(Bax, Bcl2, PARP at 1:1000 dilution) for 8–12 h at 4°C
followed by detection using peroxidase-conjugated sec-
ondary antibodies and Super Signal West Pico Chemilu-
minescence Substrate (Thermofisher scientific, USA).
Equal protein loading was detected by probing the mem-
brane with β-actin antibodies.Figure 4 Cell cycle analysis: Cells exposed to different concentrations
(c) 50 μg/ml (d) 100 μg/ml. Bar graph represents the % cells at S phase (mRelease of cytochrome c from mitochondria was mea-
sured by immunoblot assay as previously described [16]
with some modifications. Briefly, cells were washed once
with ice-cold PBS and gently lysed for 30 s in 80 μl ice-
cold lysis buffer (250 mM sucrose, 1 mM EDTA (ethyl-
ene diamine tetra acetic acid), 0.05% digitonin, 25 mM
Tris, pH 6.8, 1 mM dithiothrietol, 1 mg/ml aprotinin,
1 mg/ml pepstatin, 1 mg/ml leupeptin, 1 mM PMSF
(phenyl methane sulfonyl fluoride) and 1 mM benzami-
dine). Lysates were centrifuged at 12,000 × g at 4°C for
5 min to obtain the extracts (cytosolic extracts free of
mitochondria). Supernatants were electrophoresed on 8-of EAPL (25, 50 and 100 μg/ml) for 24 h. (a) Control (b) 25 μg/ml
ean ± SEM).
Figure 5 Immunoblot analysis: Lane 1: 0 μg; lane 2: 25 μg;
lane 3: 50 μg; lane 4: 100 μg. Equal loading confirmed by β-actin.
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ern blot using cytochrome c antibody.
HPLC standardization
The sample was analyzed by reverse phase-high perform-
ance liquid chromatography using Shimadzu class LC-
20 AD HPLC system, composed by a binary pump, 100 μl
injection loop, Photo Diode Array (PDA) detector set at
250–350 nm under room temperature with a flow rate of
0.9 ml/min. Phenomenex Luna 5_ C-18 (2) (150 mm×
4.6 mm) was used as stationary phase. The mobile phase
constituted 0.5% formic acid and acetonitrile (70:30%, v/v).
A serial dilution of standard rutin resulting to 15 ppm,
25 ppm, 50 ppm, 75 ppm and 100 ppm solutions were
used for preparing calibration curve (Concentration Vs
Area Under Curve). The amount of rutin present in EAPL
was quantified from the standard graph.
Statistical analysis
All experiments were carried out in triplicate. Data were
expressed as means ± SEM. Differences were evaluated by
one-way analysis of variance (ANOVA) test completed by
Dennett’s test. * denotes p < 0.05, ** denotes p < 0.01 and
*** denotes p < 0.001. The 50% inhibitory concentration
(IC50) was calculated by nonlinear regression curve with
the use of Graphpad Prism version 5.0 for Windows
(Graphpad Prism Software, San Diego, CA, USA).
Results and discussion
Phytochemical analysis
The aqueous ethanolic extract was found to contain
steroids, terpenoids, flavonoids and/or their glycosides,
tannins and carbohydrates. The alkaloids, coumarins,
cardiac glycosides were absent.
The determination of IC50 by MTT assay
In an effort to gain mechanistic insights of EAPL-induced
apoptosis on K562 cells, the anti-proliferative activity was
evaluated by MTT assay along with normal (HEK 293)
cells. As shown in Figure 1a, a dose-dependent decrease
in the growth of cells was observed with increasing con-
centrations of EAPL and no significant difference was
observed in the growth of normal cells. IC50 value of
EAPL on K562 cells was calculated to be 40 ± 0.01 μg/ml
(mean ± SEM) at 24 h by using Graphpad Prism. As a
positive control, carvacrol was included in the study and
the IC50 was determined to be was 110 μg/ml (Figure 1b)
as reported earlier [17]. The assay suggests that EAPL is
more specific towards cancer cells and ~3 fold more ef-
fective compare to carvacrol.
Morphological observations
In order to evaluate the cause of growth inhibition of
K562 cells by EAPL, characteristic features of apoptosiswere studied. Apoptosis or programmed cell death is
recognized by characteristic pattern of morphological,
biochemical, and molecular changes occurring in a cell
[18]. EAPL treated (100 μg/ml) cells for 24 h showed
prominent morphological changes resembling cell shrink-
age with rounding of cells and formation of membrane
blebs (Figure 2b) compare to control (Figure 2a) cells
which is a characteristic feature of apoptosis as evidenced
by microscopic studies.
Annexin V assay
Redistribution of phosphatidylserine to the external
side of the cell membrane occurs due to perturbation in the
cellular membrane, is one of the biochemical features of
apoptosis [19]. Annexin V, a recombinant phosphatidylserine-
binding protein, interacts strongly and specifically with
phosphatidylserine residues and is used for the detection
of apoptosis [20]. Staining of cells with 7-AAD discrimin-
ate early apoptotic and dead cells. From Figure 3, the vast
majority of K562 cells in the untreated (3a) were healthy
and thus unstained for annexin V and 7-AAD. Where-
as cells treatment with EAPL resulted in dose dependent
increase in the Annexin V and 7-AAD positive cells
(3b, 3c, 3d) demonstrating induction of apoptosis.
Cell cycle analysis
Loss of DNA content is a typical characteristic feature of
apoptosis. Staining of cells with propidium iodide (PI)
and analyzing by flow cytometer would helps in evaluat-
ing the cells at different (subG0/G1, G1, S, G2/M)
phases of cell cycle. K562 cells were exposed with differ-
ent concentrations (25, 50, 100 μg/ml) of EAPL for 24 h,
washed and harvested and then analyzed in flow
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of the cell cycle was calculated and shown in Figure 4. A
dose dependent increase of sub G0/G1 phase (apoptotic
peak) and decrease of S phase was observed, indicating
the induction of apoptosis and inhibition of DNA syn-
thesis in S phase. These results are in accordance with
the previous results [14].
p53 mediated apoptosis
Further to understand the underlying molecular mechan-
ism of apoptosis induced by EAPL, activation of the p53-
mediated signaling network was evaluated. Modulation of
p53 levels was evaluated by Western blot analysis using
p53 antibody in K562 cells treated with different concen-
trations (25, 50, 100 μg/ml). The results showed an in-
crease in p53 levels in a dose dependent mannerFigure 6 MitoPotential analysis. K562 cells treated with (25, 50, and 100
D-Dead cells. (a) Control (b) 25 μg/ml (c) 50 μg/ml (d) 100 μg/ml. Bar grap(Figure 5a). Bax homodimers are inducers of apoptosis
whereas Bax-Bcl2 heterodimer formation results in cell
survival. Both Bax and Bcl2 are transcriptional targets of
p53 [21,22]. The levels of the pro-apoptotic protein Bax
and anti-apoptotic protein Bcl2 were measured using
Western blot. There is a significant decrease in the levels
of Bcl2 (Figure 5c) with a little or no alteration in Bax
protein, indicating the formation of Bax homodimers
(Figure 5b). These changes resulted in increase within
the Bax/Bcl2 ratio thereby pushing the cellular balance
in the direction of apoptosis. Subsequently, proliferating
cell nuclear antigen (PCNA), the marker of dividing cells,
specifically inhibited by p53 [23,24] was also studied. The
results illustrate a dose-dependent decrease in the ex-
pression of PCNA, suggesting induction of apoptosis
(Figure 5d).μg/ml) or without EAPL for 24 h and analyzed by flow cytometer.
h represents the % dead/apoptotic cells (mean ± SEM).
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Loss of mitochondrial inner transmembrane potential
(ΔΨm) is often [25-28], but not always [29,30] observed
to be associated with the early stages of apoptosis. Col-
lapse of this potential is believed to coincide with the
opening of the mitochondrial permeability transition
pores, leading to the release of cytochrome c into
the cytosol. In cytoplasm, cytochrome c combines with
caspase-9, Apaf-1 and dATP to form the apoptosomeFigure 7 (a) Immunoblot analysis of Cyt c expression in EAPL treated
(b) Multicaspase analysis. K562 cells treated with (25, 50, and 100 μg/ml) or
(b) 25 μg/ml (c) 50 μg/ml (d) 100 μg/ml. Bar graph represents the % of cascomplex [31] which in turn activates caspase- 9, -3 and
−7. The alteration in membrane mitopotential of the
apoptotic cells was determined by flow cytometry and
the results showed a dose dependent decrease in the
membrane potential (Figure 6). Further the release of
cytochrome c from mitochondria into cytosol was ana-
lyzed by Western blot analysis in cytosolic fractions of
EAPL treated cells. There is a dose dependent increase
in the levels of cytochrome c in the cytoplasm indicating(25, 50, 100 μg/ml) K562 cells. Equal loading confirmed by β-actin.
without EAPL for 24 h and analyzed by flow cytometer. (a) Control
pase active cells (mean ± SEM).
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vation of multicaspases was determined by FACS ana-
lysis and the results clearly demonstrated an increase in
multicaspases activation with increase in concentration
of EAPL (Figure 7b).
Cleavage of PARP
PARP (poly (ADP-ribose) polymerase) catalyzes the poly
ADP-ribosylation of a variety of nuclear proteins with
NAD as substrate. Upon DNA damage, PARP gets acti-
vated and depletes NAD as well as ATP in an attempt to
repair the broken DNA. During apoptosis, caspase-3
inactivates PARP by cleaving it into 83 and 24 kDa frag-
ments and thereby preserves ATP resources of the cell
for apoptosis [32,33]. Results from immunoblot analysis
using antibody that recognizes uncleaved (116 kDa) and
cleaved (83 kDa) fragments of PARP, clearly demonstrate
dose dependent inactivation of PARP in EAPL treated
cells (Figure 8). The above mentioned studies clearly
demonstrate that EAPL induces apoptosis in K562 cells
by intrinsic death pathway.
HPLC standardization
Under the set of given analytical conditions, the reten-
tion time of standard rutin was observed as 3.8 min (see
Additional file 1: Figure S1). The retention time of Rutin
present in the sample was found to be identical (see
Additional file 1: Figure S1) and the amount of Rutin in
EAPL was calculated to be 0.024 % (w/w).
Conclusion
In conclusion, the current work demonstrates the anti-
proliferative effect of EAPL to induce programmed cell
death in chronic myeloid leukemia (K562) cells with an
IC50 of 40 ± 0.01 μg/ml, showing its anticancer property.
It also explains the underlying molecular proceedings
occurring in the presence of EAPL. Together, morpho-
logical changes such as cell shrinkage, rounding of cells,
membrane blebbing, activation of p53, cell cycle arrest
at S phase, increase in annexin V positive cells, increase
in Bax/Bcl2 ratio, decrease in mitochondrial membrane
potential and increase in cytochrome c release fromFigure 8 Immunoblot analysis of PARP cleavage in EAPL
treated (25, 50, 100 μg/ml) K562 cells. Equal loading confirmed
by β-actin.mitochondria, increase in caspase activity, cleavage of
PARP and inhibition of PCNA demonstrate the molecu-
lar mechanism of programmed cell death by EAPL.
Many of the natural antioxidants have been reported for
anti cancer activity by the mechanism not yet clear but
one example is curcumin induces apoptosis via a ROS-
associated mechanism that converges on JNK activation,
and to a lesser extent via a parallel ceramide-associated
pathway [34]. Thus, the current work clearly reveals that
EAPL could be a potent anti-cancer agent against
chronic myeloid leukemia. Study of individual phytocon-
stituents of the EAPL extract may form the basis for fu-
ture studies.
The use of natural drugs or food products rich in anti-
oxidant property has been drawn great attention by
many scientists for chemotherapeutic purposes, in part
because these foods are generally recognized as safe. But
natural drugs and food components showing strong
antioxidant potential cannot always result in anticancer
activities since the biological process of cancer develop-
ment may be affected by phytochemicals via different
mechanisms in addition to antioxidant effects. Many
cell-culture based studies have been performed in an at-
tempt to elucidate the relationship between antioxidant
activities and anticancer properties of some plant-based
drugs. To this end, conflicting findings were observed.
Even though mechanism of antitumor activity of most of
the plant based drugs has been established, still it is un-
clear with respect to mechanism of cancer cell death
based on antioxidant property [35]. Many studies
propose that there are additional functions accountable
for the antitumor activity produced by these plant-based
drugs that go beyond their antioxidant ability. Extensive
molecular and metabolic studies are required to discover
these other pathways [36]. Beside the use of cell-culture
models, animal experiments and human clinical trials
should be employed to explore the possible applications
of phytochemical antioxidant rich drugs. These studies
will provide more physiological insight into whether
antioxidant capacities of plant base drugs are directly
linked to their anticancer activities.
Additional file
Additional file 1: Figure S1A: HPLC chromatogram of standard Rutin
(15, 25, 50, 75 and 100 ppm) and sample (EAPL). Figure S1B: HPLC
chromatogram of ethanolic extract of aerial parts of Pupalia lappacea.
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